Drugs / Norgestimate-ethinyl estradiol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00752635 | Sep 2004 → Sep 2005 | acne | Johnson & Johnson Taiwan Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Norgestimate-ethinyl estradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00752635 ↗ |
| Known as | noregestimate-ethinyl estradiol | “TriCilest (noregestimate-ethinyl estradiol), 0.18mg-0.035mg or 0.215mg-0.035mg or 0.25mg-0.035mg, Oral admistration” NCT00752635 ↗ |
| Route | Oral | “Oral admistration” NCT00752635 ↗ |